JewishStatusOpen the app

Kol Haolam · Jul 16, 2026

Kol Haolam — photo status

The FDA approved Merck's Lipfendra (enlicitide), the first daily pill of its kind to lower LDL ("bad") cholesterol beyond what statins alone can achieve. Clinical trials found it cut LDL by up to 60% over six months.

The FDA approved Merck's Lipfendra (enlicitide), the first daily pill of its kind to lower LDL ("bad") cholesterol beyond what statins alone can achieve. Clinical trials found it cut LDL by up to 60% over six months.

Watch in the app All of Kol Haolam's statuses

More from Kol Haolam